Forward BIOLABS, in partnership with BioForward Madison, announced today the second round of awardees of the Innovation to Commercialization Pipeline (ICP) program.

The awardees from the Madison area are aMBR genomics, Cellular Logistics, FAR Biotech and Plumb Pharmaceuticals.

“The evidence is in–by supporting milestone-driven projects, ICP is strengthening Wisconsin’s pipeline of companies positioned to attract follow-on investment,” Forward BIOLABS CEO and Co-Founder Jessica Martin Eckerly said in a statement. “Importantly, these achievements are not solely the result of ICP funding; they reflect each team’s continued efforts to build momentum by successfully executing on a series of company-specific milestones. The goal is not only better solutions for patients, but also to build companies that become Wisconsin’s next employers.”

According to a release, the 10 awardees span a broad range of Wisconsin biohealth, including medical devices, diagnostics, therapeutics and life sciences.